Your Yourlocation: Home > Application of tiotropium bromide(136310-93-5) in the treatment of Asthma

Recent studies have evaluated the value of long-acting anti-muscarinic relaxant (LAMA) such as tiotropium bromide(136310-93-5), as a maintenance drug in patients with chronic asthma.

Tiotropium bromide(136310-93-5) appeared early in 2000 for at least 24 hours and is recommended for daily dosing as a maintenance drug for COPD. Tiotropium bromide can be administered in the form of dry powder (DPI), but a new form of administration of soft fog inhalation (SMI) has recently emerged.

A comparison of tiotropium in the treatment and double the ICS dose (with a major advantage) compared with asthma patients with FEV1 <70% despite the large number of ICS symptoms in use but not effective control, or with tiotropium bromide And the addition of salmeterol (secondary non-inferiority comparisons).

The addition of tiotropium was superior to doubling the ICS dose at the primary end point, morning PEF, and secondary endpoint (FEV1, symptom score, and days of asthma control). At the morning PEF and other end points, tiotropium was not inferior to salmeterol.

A randomized, double-blind, crossover study examined the safety and efficacy of tiotropium bromide(136310-93-5) compared with placebo in uncontrolled patients with severe asthma. Although high-dose ICS plus LABA was used in the trial, the active treatment group was superior to the placebo group in terms of peak FEV1, primary endpoint, and so on.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved